335 related articles for article (PubMed ID: 27935748)
21. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
[TBL] [Abstract][Full Text] [Related]
22. Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas.
Ramone T; Romei C; Ciampi R; Tacito A; Piaggi P; Torregrossa L; Ugolini C; Elisei R
Endocrine; 2019 Sep; 65(3):623-629. PubMed ID: 31278686
[TBL] [Abstract][Full Text] [Related]
23. Sprouty1 is a candidate tumor-suppressor gene in medullary thyroid carcinoma.
Macià A; Gallel P; Vaquero M; Gou-Fabregas M; Santacana M; Maliszewska A; Robledo M; Gardiner JR; Basson MA; Matias-Guiu X; Encinas M
Oncogene; 2012 Aug; 31(35):3961-72. PubMed ID: 22158037
[TBL] [Abstract][Full Text] [Related]
24. Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer.
Lopergolo A; Perrone R; Tortoreto M; Doria F; Beretta GL; Zuco V; Freccero M; Borrello MG; Lanzi C; Richter SN; Zaffaroni N; Folini M
Oncotarget; 2016 Aug; 7(31):49649-49663. PubMed ID: 27351133
[TBL] [Abstract][Full Text] [Related]
25. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells.
Starenki D; Hong SK; Lloyd RV; Park JI
Oncogene; 2015 Aug; 34(35):4624-34. PubMed ID: 25435367
[TBL] [Abstract][Full Text] [Related]
26. LRIG1 negatively regulates RET mutants and is downregulated in thyroid cancer.
Lindquist D; Alsina FC; Herdenberg C; Larsson C; Höppener J; Wang N; Paratcha G; Tarján M; Tot T; Henriksson R; Hedman H
Int J Oncol; 2018 Apr; 52(4):1189-1197. PubMed ID: 29436694
[TBL] [Abstract][Full Text] [Related]
27. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
[TBL] [Abstract][Full Text] [Related]
28. A Novel Germline Deletion of p.C630 in RET Causes MTC and Promotes Cell Proliferation and Sensitivity to Pralsetinib.
Ma X; Ma X; Chin L; Zhu Z; Han H
J Clin Endocrinol Metab; 2022 Aug; 107(9):2636-2643. PubMed ID: 35689816
[TBL] [Abstract][Full Text] [Related]
29. ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma.
Luo J; Xia Y; Yin Y; Luo J; Liu M; Zhang H; Zhang C; Zhao Y; Yang L; Kong L
Theranostics; 2019; 9(21):6334-6353. PubMed ID: 31534554
[No Abstract] [Full Text] [Related]
30. Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells.
Bertazza L; Barollo S; Radu CM; Cavedon E; Simioni P; Faggian D; Plebani M; Pelizzo MR; Rubin B; Boscaro M; Pezzani R; Mian C
J Cell Mol Med; 2015 Sep; 19(9):2244-52. PubMed ID: 26081844
[TBL] [Abstract][Full Text] [Related]
31. Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.
Rodríguez-Antona C; Muñoz-Repeto I; Inglada-Pérez L; de Cubas AA; Mancikova V; Cañamero M; Maliszewska A; Gómez A; Letón R; Leandro-García LJ; Comino-Méndez I; Sanchez L; Alvarez-Escolá C; Aller J; Cascón A; Robledo M
Endocr Relat Cancer; 2013 Aug; 20(4):611-9. PubMed ID: 23780998
[TBL] [Abstract][Full Text] [Related]
32. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.
Mian C; Pennelli G; Barollo S; Cavedon E; Nacamulli D; Vianello F; Negro I; Pozza G; Boschin IM; Pelizzo MR; Rugge M; Mantero F; Girelli ME; Opocher G
Eur J Endocrinol; 2011 Jun; 164(6):971-6. PubMed ID: 21422198
[TBL] [Abstract][Full Text] [Related]
33. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
[TBL] [Abstract][Full Text] [Related]
34. Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma.
Rapa I; Saggiorato E; Giachino D; Palestini N; Orlandi F; Papotti M; Volante M
J Clin Endocrinol Metab; 2011 Jul; 96(7):2146-53. PubMed ID: 21543427
[TBL] [Abstract][Full Text] [Related]
35. Targeting RET to induce medullary thyroid cancer cell apoptosis: an antagonistic interplay between PI3K/Akt and p38MAPK/caspase-8 pathways.
Mazumdar M; Adhikary A; Chakraborty S; Mukherjee S; Manna A; Saha S; Mohanty S; Dutta A; Bhattacharjee P; Ray P; Chattopadhyay S; Banerjee S; Chakraborty J; Ray AK; Sa G; Das T
Apoptosis; 2013 May; 18(5):589-604. PubMed ID: 23329180
[TBL] [Abstract][Full Text] [Related]
36. Proteomic Identification of DNA-PK Involvement within the RET Signaling Pathway.
Burdine LJ; Burdine MS; Moreland L; Fogel B; Orr LM; James J; Turnage RH; Tackett AJ
PLoS One; 2015; 10(6):e0127943. PubMed ID: 26065416
[TBL] [Abstract][Full Text] [Related]
37. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
38. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
Lopergolo A; Nicolini V; Favini E; Dal Bo L; Tortoreto M; Cominetti D; Folini M; Perego P; Castiglioni V; Scanziani E; Borrello MG; Zaffaroni N; Cassinelli G; Lanzi C
J Clin Endocrinol Metab; 2014 Feb; 99(2):498-509. PubMed ID: 24276455
[TBL] [Abstract][Full Text] [Related]
39. Calcium/Calmodulin-dependent protein kinase II and its endogenous inhibitor α in medullary thyroid cancer.
Russo E; Salzano M; De Falco V; Mian C; Barollo S; Secondo A; Bifulco M; Vitale M
Clin Cancer Res; 2014 Mar; 20(6):1513-20. PubMed ID: 24449826
[TBL] [Abstract][Full Text] [Related]
40. A 6-Base Pair in Frame Germline Deletion in Exon 7 Of RET Leads to Increased RET Phosphorylation, ERK Activation, and MEN2A.
Latteyer S; Klein-Hitpass L; Khandanpour C; Zwanziger D; Poeppel TD; Schmid KW; Führer D; Moeller LC
J Clin Endocrinol Metab; 2016 Mar; 101(3):1016-22. PubMed ID: 26765577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]